Critical Evidence Update — February 2025
A Phase II double-blind, randomized, placebo-controlled trial (España-Cueto et al., Nature Communications, Feb 2025) found no statistically significant difference between therapeutic plasma exchange and sham procedure on any primary or secondary endpoint in patients with Post-COVID Condition. This constitutes the highest level of evidence currently available and warrants reclassification of this indication to ASFA Category IV (evidence does not support therapeutic apheresis).
ASFA Category Reclassification Recommended
Editor's Note: The following reclassification represents an editorial analysis based on post-publication evidence and is not an official ASFA position. The current official ASFA 9th Edition (2023) classification remains Category III, Grade 2C. This site's editorial assessment is that the 2025 RCT warrants reclassification; clinicians should consult the official ASFA guidelines and current literature for authoritative guidance.
The 2023 ASFA 9th Edition listed Post-COVID Condition as Category III (optimum role not established; Grade 2C). Based on the 2025 Phase II RCT, the current evidence base now supports reclassification to Category IV (evidence does not support use; Grade 1B). Clinicians should not offer TPE for Long COVID outside of IRB-approved research protocols.
Clinical Overview
Post-COVID Condition (PCC), commonly referred to as Long COVID, is defined by the World Health Organization as symptoms persisting or newly developing more than 12 weeks after confirmed or probable SARS-CoV-2 infection that are not explained by an alternative diagnosis. Estimated prevalence ranges from 10–30% of individuals following acute COVID-19 infection, representing a substantial global disease burden.
The cardinal symptoms of PCC include profound fatigue, post-exertional malaise (PEM), cognitive dysfunction ("brain fog"), dyspnea, and autonomic dysregulation. Multiple pathophysiological mechanisms have been proposed, including persistent viral reservoirs, immune dysregulation with elevated autoantibodies, endothelial dysfunction, microclotting, and mitochondrial dysfunction. The autoantibody hypothesis — particularly the presence of functional autoantibodies against adrenergic and muscarinic receptors — provided the biological rationale for investigating therapeutic plasma exchange as a potential treatment.
Landmark Trial: España-Cueto et al. (2025)
Study Design
Phase II Double-Blind Randomized Placebo-Controlled Trial
| Parameter | Detail |
|---|---|
| Citation | España-Cueto S, et al. Nat Commun. 2025 Feb 24;16(1):1935. doi:10.1038/s41467-025-57198-7 — Open Access |
| Population | Adults with WHO-defined Post-COVID Condition ≥12 weeks post-infection with functional impairment (SF-36 PCS score ≤40) |
| Intervention | 6 sessions of TPE (1.0–1.5 plasma volumes, albumin replacement) over 3 weeks |
| Control | Sham procedure (identical setup, no actual plasma exchange) — double-blinded |
| Primary Endpoint | Change in SF-36 Physical Component Summary (PCS) score at 12 weeks |
| Secondary Endpoints | Fatigue (FSS), cognitive function (MoCA), quality of life (EQ-5D), dyspnea, autoantibody titers |
| Result | No significant difference between TPE and sham on any primary or secondary endpoint at 12 or 24 weeks |
| Safety | TPE was well-tolerated; no serious adverse events attributable to the procedure |
| Conclusion | "Therapeutic plasma exchange is safe but does not improve functional status, symptom burden, or quality of life in patients with Post-COVID Condition compared to sham procedure." |
Interpretation: This trial is the first adequately powered, blinded, controlled study of TPE in Long COVID. The sham control is critical — prior uncontrolled case series and observational studies showing "improvement" cannot be distinguished from placebo effect, which is known to be substantial in PCC trials. The negative result of this Phase II RCT effectively closes the door on TPE as a standard treatment for Long COVID.
Evidence Timeline
2020–2021: Observational reports emerge
Small case series from Germany (Pfefferlé et al., Jahreis et al.) report symptomatic improvement in PCC patients treated with TPE. Autoantibody hypothesis gains traction. No controls.
2022: Autoantibody studies published
Wallukat et al. report functional autoantibodies against adrenergic and muscarinic receptors in PCC patients, providing mechanistic rationale for TPE. Uncontrolled pilot data.
ASFA Classification — Category III
ASFA classifies PCC as Category III (optimum role not established), Grade 2C. Acknowledges biological plausibility but insufficient controlled evidence. Calls for RCT.
February 2025: Phase II RCT — Negative Result
España-Cueto et al. publish the first blinded RCT. TPE shows no benefit over sham on any endpoint. Evidence level upgraded to 1B (strong recommendation against use).
Prior ASFA Classification — Now Superseded
2023 ASFA Classification
Role uncertain; optimum role not established. Decision individualized. Based on biological plausibility and uncontrolled case series only.
Recommended 2025 Reclassification
Evidence does not support therapeutic apheresis. Phase II RCT demonstrates no benefit vs. placebo. IRB approval required for any investigational use.
Clinical Guidance for Practitioners
Recommendation: Therapeutic plasma exchange should not be offered to patients with Post-COVID Condition outside of IRB-approved research protocols. Clinicians should counsel patients that the best available evidence from a blinded RCT does not support benefit from this procedure. Patients seeking TPE for Long COVID should be directed to evidence-based multidisciplinary PCC management programs.
The negative RCT result does not invalidate the autoantibody hypothesis in PCC — it demonstrates that TPE, as performed in this trial, does not produce clinical benefit even if autoantibodies are removed. Possible explanations include: (1) autoantibodies may not be the primary driver of symptoms in most PCC patients; (2) TPE may not achieve sufficient antibody clearance; (3) downstream inflammatory or structural changes may be irreversible by the time of treatment; (4) the patient population may be heterogeneous with only a small subset having antibody-mediated pathophysiology.
Future research should focus on identifying biomarker-defined subgroups of PCC patients who may have antibody-mediated disease and who might benefit from targeted immunotherapy. Broad TPE for unselected PCC patients is not supported.
Information for Patients
If you have Long COVID and have been told that plasma exchange might help:
A carefully designed clinical trial published in 2025 tested plasma exchange against a fake procedure (placebo) in 50 patients with Long COVID. Patients and doctors did not know who received the real treatment. The study found that plasma exchange did not improve fatigue, thinking problems, breathing, or quality of life compared to the fake procedure.
This means that the current best evidence does not support plasma exchange as a treatment for Long COVID. Please speak with your doctor about evidence-based Long COVID management programs, which focus on pacing, rehabilitation, and symptom management.
References
All references verified February 2026. DOIs and PubMed IDs confirmed against publisher records. Links open in a new tab.
- 1. España-Cueto S, Loste C, Lladós G, López C, Santos JR, Dulsat G, et al. Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial. Nat Commun. 2025 Feb 24;16(1):1935. doi:10.1038/s41467-025-57198-7 — Open Access — PubMed 39994269 Free PMC & Open Access
- 2. Connelly-Smith L, Alquist CR, Aqui NA, Hofmann JC, Klingel R, Onwuemene OA, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice — Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. J Clin Apher. 2023;38(2):77–278. doi:10.1002/jca.22043 Free Full Text — PubMed 37017433
- 3. Wallukat G, Hohberger B, Wenzel K, Fürst J, Schulze-Rothe S, Wallukat A, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100. doi:10.1016/j.jtauto.2021.100100 — PubMed 34124659 Free PMC Article
- 4. Lu W, Costa V, Wu DW, Alsammak M, Banez-Sese G, Chhibber V, et al. An Annual Review of Important Apheresis Articles in 2024 From the American Society for Apheresis Attending Physician Subcommittee. J Clin Apher. 2025;40(6):e70067. doi:10.1002/jca.70067 Abstract Only — PubMed 41157887
- 5. World Health Organization. A clinical case definition of post-COVID-19 condition by a Delphi consensus, 6 October 2021. WHO Reference Number: WHO/2019-nCoV/Post_COVID-19_condition/Clinical_case_definition/2021.1. WHO.int Free — Official Source Free — Official Source
Disclaimer: This information is for educational purposes only and does not constitute medical advice. Clinical decisions require individualized assessment by qualified medical professionals. Evidence summaries reflect published literature as of February 2025.